ライフサイエンスコーパス: malaria

1 e sclerosis, cerebral ischemia, and cerebral malaria.

2 for diagnosing infectious diseases, such as malaria.

3 tion is a key challenge for vaccines against malaria.

4 oma and lactic acidosis in severe falciparum malaria.

5 ng sickness and recovery in a mouse model of malaria.

6 ldren admitted to hospital with P falciparum malaria.

7 sfunction, and mortality in a mouse model of malaria.

8 aria and 1,369 (1,244-1,506) ng/ml in severe malaria.

9 e cohorts of Malawian children with cerebral malaria.

10 ction of 'irresistible' drugs for combatting malaria.

11 l facilitate the rational vaccine design for malaria.

12 enoquine are required for the elimination of malaria.

13 r years, then reactivate causing symptomatic malaria.

14 rug of a single-dose combination therapy for malaria.

15 the largest global burdens of P. falciparum malaria.

16 ical development as a treatment for P. vivax malaria.

17 bmicroscopic malaria and diagnosis of severe malaria.

18 -Th1) Ag-expT cells throughout the course of malaria.

19 strategies to prevent and/or treat placental malaria.

20 ventions are needed to control and eliminate malaria.

21 cells essential for host protection against malaria.

22 d's most deadly diseases, including AIDS and malaria.

23 caspases-1/11/GSDM-D in the pathogenesis of malaria.

24 (PfMyoA), a first order drug target against malaria.

25 y that it is under positive selection due to malaria.

26 c changes in the treatment and prevention of malaria.

27 d safe drugs for prevention and treatment of malaria.

28 Malaria-071, a controlled human malaria infection trial,

29 compared with tuberculosis ($156 per DALY), malaria ($125 per DALY), and pneumonia ($33 per DALY).

30 verity, being 7 (4-12) ng/ml in asymptomatic malaria, 843 (655-1,084) ng/ml in uncomplicated malaria

31 Malaria, a parasitic infection caused by Plasmodium para

32 laria (CM) is the most common form of severe malaria, accounting for the vast majority of childhood d

33 ce, anaemia, and risk of subsequent clinical malaria across transmission settings.

34 lts suggest a marked geographic catchment of malaria admission around the four sentinel hospitals alt

35 s was used to predict hospital catchment for malaria admissions adjusting for spatial distance.

36 From 5766 malaria admissions, 5486 (95.14%) were linked to specifi

37 Preventive treatment of malaria among school-aged children significantly decreas

38 erebral malaria while 1001 (10%) were severe malaria anaemia.

39 aria, 843 (655-1,084) ng/ml in uncomplicated malaria and 1,369 (1,244-1,506) ng/ml in severe malaria.

40 lobal challenge of over 200 million cases of malaria and 400 000 deaths worldwide, with the majority

41 Abs showing the best performance to classify malaria and bacteremia patients.

42 tions, including detection of submicroscopic malaria and diagnosis of severe malaria.

43 Among the other diseases, malaria and diarrhoea have a large disease burden in Ind

44 Adjustment for malaria and fever-recovery-related QT lengthening is nec

45 uman immunodeficiency virus (HIV) infection, malaria and influenza, effective vaccinations are still

46 d dysentery, and a fifth fewer deaths due to malaria and pneumonia.

47 icularly human immunodeficiency virus (HIV), malaria and tuberculosis.

48 cidence of hospitalisations or deaths due to malaria and uncomplicated clinical malaria remained high

49 to the understanding of the pathogenesis of malaria and will facilitate the rational vaccine design

50 Multiplexed seroprofiles for EBV, malaria, and KSHV were generated for 266 eBL patients, 7

51 Recent identification of an endogenous malaria antigen that stimulates robust T(RM)-mediated im

52 equently results in exposure of the fetus to malaria antigens in utero, while the immune system is st

53 he assumption that individuals infected with malaria are clustered within households or neighbourhood

54 imitations of systems-based studies of human malaria are discussed.

55 Recent gains in the fight against malaria are threatened by the emergence and spread of ar

56 to Plasmodium spp., the parasite that causes malaria, are critical for control of parasitemia and ass

57 Plasmodium species, the causative agents of malaria, are needed.

58 iduals; 11 studies), and subsequent clinical malaria (ARR 0.50, 0.39-0.60; p<0.0001; 1815 individuals

59 Plasmodium vivax is an important cause of malaria, associated with a significant public health bur

60 One malaria-associated inpatient death was observed during t

61 nets have driven considerable reductions in malaria-associated morbidity and mortality in Africa sin

62 he blood stage is responsible for almost all malaria-associated morbidity and mortality.

63 s and the frequency distribution of P. vivax malaria attacks experienced by each individual over 12 m

64 of cases, for reasons we do not understand, malaria becomes severe and life threatening.

65 The greatest impact on malaria burden could be as a result of interruption of p

66 In Africa, where malaria burden is highest, bednets treated with pyrethro

67 transfusion might benefit some patients with malaria but could potentially harm others.

68 sts (RDTs) are the main diagnostic tools for malaria but fail to detect low-density parasitemias that

69 nfections, contribute to the pathogenesis of malaria by inducing the clearance of uninfected erythroc

70 n. funestus and a corresponding reduction of malaria case count among out-patients.

71 Malaria case counts among febrile patients within IRS ar

72 mission unit as the area contributing 95% of malaria cases diagnosed at the catchment facility locate

73 Over 200 million malaria cases globally lead to half-million deaths annua

74 ed parasitological confirmation of suspected malaria cases, especially when skilled microscopists are

75 Malaria caused by Plasmodium falciparum manifests in man

76 Malaria caused by the apicomplexan parasite Plasmodium f

77 f principle, we applied this approach to the malaria-causing parasite Plasmodium falciparum, an organ

78 Malaria-causing parasites have a life cycle with unique

79 ildren 18 months to 12 years old with severe malaria (cerebral malaria, n = 253 or severe malarial an

80 Seasonal malaria chemoprevention (SMC) is a novel strategy to red

81 and Uganda to determine whether 3 months of malaria chemoprevention could reduce morbidity and morta

82 istence may lead to lasting breakthroughs in malaria chemotherapy that can prevent recrudescences and

83 terval but are not consistently collected in malaria clinical trials.

84 Cerebral malaria (CM) is the most common form of severe malaria,

85 ecific fatal pathologies, including cerebral malaria (CM), driven by a high parasite load, leading to

86 ignificantly more likely to be infected with malaria, compared to those that survived insecticidal ex

87 hresholds among African children with severe malaria complicated by these factors.

88 relationship between endothelial activation, malaria complications, and long-term cognitive outcomes

89 dicates that neutrophils have a dual role in malaria, contributing to both pathogenesis and control o

90 n Plasmodium falciparum are major threats to malaria control and elimination.

91 allenges of the private sector in developing malaria control programs, which can include extensive co

92 Advances in malaria control this century have been largely due to di

93 ening to reverse the gains that been made by malaria control(2).

94 Whilst enhanced malaria-control activities have successfully reduced the

95 r the vast majority of childhood deaths from malaria despite highly effective antiparasite chemothera

96 his study potentially open new approaches to malaria diagnosis and surveillance.

97 Quantitative malaria diagnosis is attained with little user intervent

98 e assessed the proportion of children with a malaria diagnosis who received a blood test diagnosis an

99 vailable data to characterise the effects of malaria disease and demographic factors on the QT interv

100 evidence for reducing the burden of clinical malaria disease and examine their potential for also red

101 thening is necessary to avoid misattributing malaria-disease-related QT changes to antimalarial drug

102 n a consistent increase in the proportion of malaria due to P. vivax in regions where both parasites

103 In 2016, the Zambian National Malaria Elimination Centre started programmatic mass dru

104 For malaria elimination efforts it is important to better un

105 In the context of global malaria elimination efforts, special attention is being

106 a sustained time period could contribute to malaria elimination efforts.

107 tegies may be required to eventually achieve malaria elimination in stable transmission areas of sub-

108 However, whether malaria elimination is feasible in areas of stable trans

109 and migration will help to set up achievable malaria elimination milestones and guide the creation of

110 ensitivity RDT may have limited utility in a malaria elimination setting like Haiti.

111 e national evaluation of RACD in Eswatini, a malaria elimination setting.

112 gns with dihydroartemisinin-piperaquine as a malaria elimination tool in Southern Province.

113 With the increased interest in malaria elimination, TBV and monoclonal antibodies have

114 otect this age group and advance the goal of malaria elimination, while weighing these benefits again

115 liver-stage parasites will be essential for malaria elimination.

116 om humans to mosquitoes, are key targets for malaria elimination.

117 d Anopheles mosquitoes were collected from a malaria endemic village in Ghana.

118 In remote areas of malaria-endemic countries, rapid diagnostic tests (RDTs)

119 -having been selected to high frequencies in malaria-endemic regions(1,2).

120 ndings might improve the management of PE in malaria-endemic regions.

121 ctive focal vector control (RAVC) in the low malaria-endemic setting of Zambezi (Namibia).

122 In low malaria-endemic settings, screening and treatment of ind

123 mptomatic individuals (n = 28) in an area of malaria endemicity (Lambarene, Gabon) to validate RT-RPA

124 timalarial treatments to prevent substantial malaria epidemics.

125 Following clinical malaria episodes, children had short-lived, sequence-ind

126 Malaria eradication is a top priority of the World Healt

127 Malaria eradication remains the long-term vision of the

128 Achieving global malaria eradication will require optimizing the transmis

129 g NK cells increases with age and cumulative malaria exposure.

130 The Against Malaria Foundation, UK Department for International Deve

131 ants, patients with uncomplicated falciparum malaria had shorter QT intervals (-61.77 milliseconds; 9

132 Malaria has had a major effect on the human genome, with

133 study was to develop an induced blood-stage malaria (IBSM) model of P. malariae to study parasite bi

134 rom 177 subjects from 14 induced blood stage malaria (IBSM) studies conducted at QIMR Berghofer.

135 ly associated with protection against severe malaria in heterozygotes.

136 duced the incidence of Plasmodium falciparum malaria in many areas, there has been a consistent incre

137 therapeutic potential of IL-4 against fatal malaria in Plasmodium berghei ANKA-infected C57BL/6J mic

138 Control of malaria in pregnancy (MiP) remains a major challenge in

139 rial of intermittent preventive treatment of malaria in pregnancy.

140 better community protection against clinical malaria in pyrethroid-resistant areas compared to standa

141 tor control strategies is key to eradicating malaria in the near future.

142 Severe malaria in western Kenya is still predominantly seen amo

143 stimate the effect of multiple IRS rounds on malaria incidence and hemoglobin levels in a cohort of c

144 S implementation saw the largest decrease in malaria incidence at health centers, a 13% reduction (95

145 communities to receive IRS based on observed malaria incidence at nearby health centers.

146 odels simultaneously to age-stratified vivax malaria incidence densities and the frequency distributi

147 r residual malaria transmission, with higher malaria incidence than neighbouring areas, and therefore

148 analyses were used to identify hotspots for malaria incidence, as well as malaria vector density and

149 ies that received azithromycin was lower for malaria (incidence rate ratio 0.78, 95% CI 0.66-0.92; p=

150 ible forms, including circulating rings from malaria-infected patients and artemisinin-induced quiesc

151 (IPTp-DP) versus IPTp-SP to prevent clinical malaria infection (and its sequelae) during pregnancy.

152 PfSPZ Vaccine, followed by controlled human malaria infection (CHMI) to assess vaccine efficacy offe

153 outcome) attributed to preventing placental malaria infection (mediator).

154 e 69 g, 95% CI 26 to 112), despite placental malaria infection being lower in the dihydroartemisinin-

155 Placental malaria infection complicates one quarter of all pregnan

156 outcomes, we devised a mathematical model of malaria infection that allowed host and parasite traits

157 Malaria-071, a controlled human malaria infection trial, demonstrated that administratio

158 nfected mosquito challenge (controlled human malaria infection) 3 months after immunization, a timing

159 was also correlated with host health during malaria infection.

160 eated with placebo or 20 mg KAF156 developed malaria infection.

161 otection against homologous controlled human malaria infection.

162 in Ag-expTh1 cell loss and exhaustion during malaria infection.

163 -adjusted and sex-adjusted values), clinical malaria (infection and symptoms on the basis of study-sp

164 evention (SMC) is a novel strategy to reduce malaria infections in children.

165 The clinical severity of malaria infections related strongly to the total burden

166 Plasmodium TRiC-mediated protein folding for malaria intervention.

167 We then focus on three malaria interventions with strong evidence for reducing

168 For most children, malaria is a febrile illness that resolves with time, bu

169 Malaria is an infectious disease that affects over 216 m

170 The pathology of malaria is caused by infection of red blood cells with u

171 th severe anemia in areas of Africa in which malaria is endemic have a high risk of readmission and d

172 The burden of malaria is heavily concentrated in sub-Saharan Africa (S

173 d and the incidence of experimental cerebral malaria is significantly decreased in Pbyop1Delta-infect

174 mising new compound class for treating human malaria is the imidazolopiperazines (IZP) class.

175 Malaria, lower respiratory infections, neonatal disorder

176 Red blood cell (RBC) invasion by malaria merozoites involves formation of a parasitophoro

177 on within a densely populated all-year-round malaria metropolis of over 3.5 million inhabitants situa

178 he Plasmodium falciparum induced blood-stage malaria model consisting of 2 cohorts (40 mg and 80 mg M

179 Malaria models have consistently oversimplified how mass

180 rasites has driven breakthroughs in reducing malaria morbidity and mortality.

181 nformation combined with routinely collected malaria morbidity data from the town of Mancio Lima, the

182 rect effect was measured between ITN use and malaria morbidity; however, ITN use did moderate the eff

183 Patients with severe malaria (n = 119), uncomplicated malaria (n = 91), or su

184 (N = 101) or acute uncomplicated falciparum malaria (N = 83) were recruited from 2 hospitals in Indi

185 with severe malaria (n = 119), uncomplicated malaria (n = 91), or suspected bacterial sepsis (n = 56)

186 o 12 years old with severe malaria (cerebral malaria, n = 253 or severe malarial anemia, n = 211) or

187 ional anti-CSP antibody responses in healthy malaria-naive adults (N=45) vaccinated with RTS,S/AS01.

188 Consistent with this, NK cells of malaria-naive adults upregulated PD-1 following P. falci

189 double-blind, placebo-controlled study of 36 malaria-naive adults, all CVac subjects received chloroq

190 ]) has been well tolerated and safe in >1526 malaria-naive and experienced 6-month to 65-year-olds in

191 ibed empirically to most of those who tested malaria negative.

192 ces in behavioral risk factors, incidence of malaria, or FOI by sex.

193 ttings, deaths due to HIV, tuberculosis, and malaria over 5 years could increase by up to 10%, 20%, a

194 etected using microscopy and the presence of malaria parasitaemia was identified using rapid diagnost

195 red blood cells (RBCs) on completion of the malaria parasite asexual cell cycle.

196 f targeting 20E signaling pathways to reduce malaria parasite infection in the mosquito vector and pr

197 The malaria parasite interfaces with its host erythrocyte (R

198 Disruption of PIMMS43 in the rodent malaria parasite Plasmodium berghei triggers robust comp

199 erimental crosses carried out with the human malaria parasite Plasmodium falciparum played a key role

200 cis-polyisoprenoids are more diverse in the malaria parasite Plasmodium falciparum than previously p

201 In the human malaria parasite Plasmodium falciparum, a unicellular eu

202 In the malaria parasite Plasmodium falciparum, the switch from

203 embranes, is also needed by the lethal human malaria parasite Plasmodium falciparum.

204 a group of diverse aspartic proteases in the malaria parasite Plasmodium Their functions are striking

205 ametocytes, the sexual stage responsible for malaria parasite transmission from humans to mosquitoes,

206 togenesis) within mosquitos is essential for malaria parasite transmission.

207 nd examine their potential for also reducing malaria parasite transmission.

208 We also discuss the relevance of the malaria parasite's intravacuolar lifestyle for successfu

209 content, including molecular targets in the malaria parasite, interaction data for ligands with anti

210 ined with good in vitro activity against the malaria parasite, which translated into in vivo efficacy

211 asmodium falciparum, the most virulent human malaria parasite.

212 Our results reveal malaria parasites are at least partly responsible for sc

213 During blood-stage development, malaria parasites are challenged with the detoxification

214 Human malaria parasites have complex but poorly understood pop

215 Growth rate of malaria parasites in the blood of infected subjects is a

216 Malaria parasites invade healthy red blood cells (RBCs)

217 The ability of malaria parasites to survive ART monotherapy may relate

218 compound with relevance to the physiology of malaria parasites(10,11).

219 d erythrocytes in response to infection with malaria parasites, but the extent of this phenomenon rem

220 sider the mechanisms that the most lethal of malaria parasites, Plasmodium falciparum, uses to sense

221 ed P. falciparum FtsH1 as a likely target in malaria parasites.

222 idence for an essential role of the PfELC in malaria pathogenesis, these structures provide a bluepri

223 flammasome activation have a limited role on malaria pathogenesis.

224 studies, rosetting has been associated with malaria pathogenesis.

225 -based insights into the mechanisms of human malaria pathology and support the existence of P. vivax-

226 Ethiopia, Plasmodium falciparum and P. vivax malaria patients and controls were examined, together wi

227 Further, we find that monocytes from malaria patients express active caspases-1, -4 and -8 su

228 In human malaria patients there is a strong correlation between a

229 Studies of malaria patients were included but analysed separately.

230 h erythropoiesis and contribute to anemia in malaria patients.

231 the TLR-triggered innate immune responses in malaria patients.

232 Malaria phenotypes were defined based on available data.

233 We focus on malaria (Plasmodium) parasites which exhibit development

234 rface coat of sporozoites and is the leading malaria pre-erythrocytic-stage vaccine candidate.

235 The malaria prevalence has declined in western Kenya, result

236 re believed to have helped to reduce average malaria prevalence in PNG from 16% in 2008 to 1% in 2014

237 als disproportionately contribute to overall malaria prevalence, morbidity, and onwards transmission.

238 ng insecticidal nets (LLINs) are the primary malaria prevention tool, but their effectiveness is thre

239 Malaria prevention tools covering the preconception peri

240 zoite (PfSPZ) vaccine is being evaluated for malaria prevention.

241 infections can enhance our understanding of malaria-protective immunity and inform the design of dis

242 NP-LF assay is as simple as the conventional malaria RDTs and requires 5 muL of whole blood as sample

243 Roughly 20% of children diagnosed with malaria received no antimalarial at all, and nearly 10%

244 hs due to malaria and uncomplicated clinical malaria remained high in the study areas (overall incide

245 The global impact of malaria remains staggering despite extensive efforts to

246 ng a high level of protection, the burden of malaria remains substantial in the 2 study areas.

247 ntial Medications for treating non-resistant malaria, rheumatoid arthritis (RA) and systemic lupus er

248 Malaria risk was directly associated with exposure to sp

249 In malaria, rosetting is described as a phenomenon where an

250 ecific recognition of gTSSA-I by non-endemic malaria sera was abolished by heat-denaturation.

251 aches have not yet been implemented in human malaria species such as P. falciparum and P. knowlesi, i

252 testing for, and treatment of this neglected malaria species.

253 rial, and it protects mice from infection by malaria sporozoites.

254 Reactive malaria strategies are predicated on the assumption that

255 tuberculosis (TB), hepatitis B, hepatitis C, malaria, strongyloidiasis, schistosomiasis, other intest

256 , and long-term cognitive outcomes in severe malaria survivors.

257 Three parasitic infections - cerebral malaria, Taenia solium cysticercosis and onchocerciasis

258 en, prescription of antimalarial therapy and malaria test results were well correlated, whereas antib

259 ion of antibiotic therapy included: negative malaria testing, reporting head, ears, eyes, nose and th

260 ecently validated PfCLK3 as a drug target in malaria that offers prophylactic, transmission blocking,

261 ood cells (RBCs; e.g., sickle cell anemia or malaria), the mechanical properties and thus shape respo

262 gers should consider preventive treatment of malaria to protect this age group and advance the goal o

263 Insecticide-treated bed nets reduce malaria transmission by limiting contact between mosquit

264 In areas where malaria transmission is peri-domestic, there are program

265 P. falciparum virulence in areas of seasonal malaria transmission is regulated so that the parasite d

266 and distribution, with a particular focus on malaria transmission potential of novel, uncharacterized

267 thin a large scale individual-based model of malaria transmission representative of a high burden, hi

268 However, common metrics of malaria transmission such as parasite prevalence are und

269 enetic and epidemiological data we defined a malaria transmission unit as the area contributing 95% o

270 constitute the major reservoir for residual malaria transmission, with higher malaria incidence than

271 educing oocyst numbers and the potential for malaria transmission.

272 asitemias that are important for maintaining malaria transmission.

273 erennial transmission area to rapidly reduce malaria transmission.

274 efficacy studies of uncomplicated falciparum malaria treated with ACT that were undertaken in regions

275 PMX inhibitors are promising candidates for malaria treatment and prevention.

276 ydrogenase (DHODH) is a validated target for malaria treatment based on our finding that triazolopyri

277 short-lived plasmablasts during experimental malaria unexpectedly hindered parasite control by impedi

278 ial to achieving unprecedented reductions in malaria until 2015 (ref.

279 Malaria vaccine candidate RTS,S/AS01 is based on the cen

280 antibodies have moved to the center stage of malaria vaccine development.

281 for preclinical and clinical applications in malaria vaccine development.

282 rythrocytes are prime targets of blood stage malaria vaccine development.

283 administration of three doses of RTS,S/AS01 malaria vaccine given at one-month intervals was inferio

284 al repeat-only, epitope-focused, protective, malaria vaccine was designed.

285 al. strengthens the case for prime-and-trap malaria vaccines and will greatly aid further investigat

286 ing adjunctive therapies and next-generation malaria vaccines.

287 econdary outcomes included the incidences of malaria, vaso-occlusive crises, and serious adverse even

288 ulted in the near elimination of the primary malaria vector An. funestus and a corresponding reductio

289 ts, as a key mediator of heat seeking in the malaria vector Anopheles gambiae Although Ir21a mediates

290 Royal Guard has the potential to improve malaria vector control and provide better community prot

291 Malaria vector control may be compromised by resistance

292 y hotspots for malaria incidence, as well as malaria vector density and associated sporozoite prevale

293 We conducted a longitudinal investigation of malaria vector host choice over 3 years and resting beha

294 liver antiparasite effector molecules to the malaria vector mosquito, Anopheles gambiae The drive sys

295 ic resistance imposes a high fitness cost in malaria vectors supporting that a resistance management

296 ications may enhance genetic connectivity of malaria vectors.

297 and implementation factors, the incidence of malaria was lower in clusters receiving rfMDA than in th

298 In 2012, an unusual outbreak of urban malaria was reported from Djibouti City in the Horn of A

299 n and 35 children with Plasmodium falciparum malaria were analyzed using protein microarrays (Protopl

300 erapy (ACT) is the main treatment option for malaria, which is caused by the intracellular parasite P

301 agnostics are also lacking for nonfalciparum malaria, which is characterized by lower density infecti

302 f which 272 (5%) were classified as cerebral malaria while 1001 (10%) were severe malaria anaemia.